J&J announces 77% response rate with RYBREVANT combination in first-line HNSCC at ESMO

Johnson & Johnson announced at ESMO Phase 1b/2 OrigAMI-4 data showing a 77% response rate and 14% complete responses with its RYBREVANT combination in first-line head and neck squamous cell carcinoma (HNSCC).

Detected & updated continuously · Source: Nebula